Finance

Lists
Why is AKTX up 3,30%?
Dive Deeper
AKTX:NASDAQ
Akari Therapeutics PLC
USD 8,77
+3,30%
(+0,28) 1D
9 Okt., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTX...
Open
USD 8,51
High
USD 8,97
Low
USD 8,20
Mkt. cap
20,04 m
Avg. vol.
72,70 k
Volume
76,45 k
52-wk high
USD 42,80
52-wk low
USD 3,02
EPS
-USD 330,40
Beta
1,43
Shares outstanding
1,14 m
No. of employees
5
Open
USD 8,51
High
USD 8,97
Low
USD 8,20
Mkt. cap
20,04 m
Avg. vol.
72,70 k
Volume
76,45 k
52-wk high
USD 42,80
52-wk low
USD 3,02
EPS
-USD 330,40
Beta
1,43
Shares outstanding
1,14 m
No. of employees
5
News stories
From web sources and news partners
About Akari Therapeutics PLC
CEO-
Employees5
Founded2004
HeadquartersTampa, Florida, Verenigde State van Amerika
Sector-
Websiteakaritx.com
Analyst ratings
Based on 3 analysts giving stock ratings to AKTX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for AKTX in the last 3 months.
Highest
Current USD 8,77
USD 30,00 (+242,08%)
Average
USD 25,50 (+190,76%)
Lowest
USD 19,50 (+122,35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Lee CFA
H.C. Wainwright
Buy
Reiterated
USD 27,00
+207,9%
10/01/2026
Matthew Venezia
Alliance Global Partners
Buy
Reiterated
USD 19,50
+122,3%
09/16/2026
Jason McCarthy
Maxim Group
Buy
Maintained
USD 30,00
+242,1%
08/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
USD 40,00
+356,1%
01/05/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
USD 7,00
-20,2%
11/19/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
249,00 k
1,09 m
1,46 m
2,08 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,98 m
2,14 m
2,17 m
2,52 m
Operating expense
2,22 m
3,23 m
3,63 m
4,60 m
Total operating expenses
2,22 m
3,23 m
3,63 m
4,60 m
Operating income
-2,22 m
-3,23 m
-3,63 m
-4,60 m
Other non operating income
253,00 k
3,20 m
274,00 k
-99,00 k
EBT including unusual items
-7,49 m
-5,21 m
-15,31 m
-4,81 m
EBT excluding unusual items
-2,12 m
-998,00 k
-3,35 m
-4,81 m
Income tax expense
-1,09 m
85,00 k
-859,00 k
-
Effective tax rate
14,53%
-1,63%
5,61%
-
Other operating expenses
-
-
-
-
Net income
-6,40 m
-5,30 m
-14,46 m
-4,81 m
Net profit margin
-
-
-
-
Earnings per share
-1,06
-
-
-
Interest and investment income
1,00 k
-
-
-
Interest expense
-121,00 k
-723,00 k
-61,00 k
-80,00 k
Net interest expenses
-120,00 k
-723,00 k
-61,00 k
-80,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,22 m
-3,22 m
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme